Sanofi books over €1B in Q2 impairment charges axing amlitelimab, balinatunfib and itepekimab, and upgrades 2026 sales guidance to ~10% growth.
Sanofi booked over €1.03 billion in impairment charges in the second quarter largely due to an eczema drug termination, with its pipeline review leading to …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sanofi discontinues amlitelimab development, citing lack of meaningful eczema benefit
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Sanofi: Belén Garijo setzt auf Innovation und Wachstum
Malin misses out on $25.9m earnout as centrepiece drug key 2021 deal is scrapped
Why Sanofi Stock Is Falling Thursday - Sanofi (NASDAQ:SNY)
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
Lucro da Sanofi recua 91,3% no 2º trimestre, para 343 milhões de euros
New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
